{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:04:22Z","timestamp":1788815062408,"version":"build-2803163510"},"reference-count":151,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaci.2026.01.027","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:55:40Z","timestamp":1770796540000},"page":"804-817.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updates in hereditary angioedema and chronic spontaneous urticaria"],"prefix":"10.1016","volume":"157","author":[{"given":"Raagini Suresh","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora U.J.","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3476-1196","authenticated-orcid":false,"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.01.027_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","article-title":"Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib3","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1016\/j.jaip.2021.08.019","article-title":"Racial and ethnic disparities in the research and care of hereditary angioedema patients in the United States","volume":"9","author":"Sylvestre","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.anai.2025.05.018","article-title":"Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database","volume":"135","author":"Castaldo","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2026.01.027_bib5","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2500\/aap.2020.41.200081","article-title":"Hereditary angioedema: pathophysiology (HAE type I, HAE type II, and HAE nC1-INH)","volume":"41","author":"Wedner","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2026.01.027_bib6","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/all.12648","article-title":"Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations","volume":"70","author":"Bork","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib7","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI77139","article-title":"Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III","volume":"125","author":"Bj\u00f6rkqvist","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.01.027_bib8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.bbrc.2006.03.092","article-title":"Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor","volume":"343","author":"Dewald","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2026.01.027_bib9","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood.2021012945","article-title":"A mechanism for hereditary angioedema caused by a lysine 311\u2013to\u2013glutamic acid substitution in plasminogen","volume":"139","author":"Dickeson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.01.027_bib10","article-title":"Mutant plasminogen in hereditary angioedema is bypassing FXII\/kallikrein to generate bradykinin","volume":"13","author":"Hintze","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.jaci.2026.01.027_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/all.13270","article-title":"Hereditary angioedema with a mutation in the plasminogen gene","volume":"73","author":"Bork","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbrc.2017.12.060","article-title":"A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor","volume":"498","author":"Dewald","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2026.01.027_bib13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","article-title":"Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema","volume":"141","author":"Bafunno","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cea.13349","article-title":"Angiopoietin-1 haploinsufficiency affects the endothelial barrier and causes hereditary angioedema","volume":"49","author":"D\u2019Apolito","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2023022254","article-title":"A mechanism for hereditary angioedema caused by a methionine-379\u2013to\u2013lysine substitution in kininogens","volume":"143","author":"Dickeson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.01.027_bib16","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/all.13869","article-title":"Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin","volume":"74","author":"Bork","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib17","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1111\/all.14454","article-title":"A myoferlin gain-of-function variant associates with a new type of hereditary angioedema","volume":"75","author":"Ariano","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12016-021-08835-8","article-title":"Pathophysiology of hereditary angioedema (HAE) beyond the SERPING1 gene","volume":"60","author":"Sharma","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10875-025-01912-z","article-title":"Expanding the genetic and clinical spectrum of hereditary angioedema with normal C1 inhibitor: novel variants and treatment insights","volume":"45","author":"Gao","year":"2025","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jaci.2021.01.011","article-title":"Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation","volume":"148","author":"Bork","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib21","article-title":"Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency","volume":"3","author":"Vincent","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2026.01.027_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jaci.2024.05.017","article-title":"DAB2IP associates with hereditary angioedema: insights into the role of VEGF signaling in HAE pathophysiology","volume":"154","author":"D\u2019Apolito","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1502325","article-title":"Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN study and CASPIAN open-label extension","volume":"16","author":"Riedl","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.amjmed.2007.08.021","article-title":"Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course","volume":"120","author":"Bork","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2500\/aap.2024.45.240010","article-title":"Hereditary angioedema with normal C1 esterase inhibitor: current paradigms and clinical dilemmas","volume":"45","author":"Radojicic","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2026.01.027_bib26","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jaip.2025.02.036","article-title":"Hereditary angioedema with normal C1 inhibitor: a quarter century of forward progress and persisting obstacles","volume":"13","author":"Christiansen","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib27","series-title":"Middleton\u2019s allergy","first-page":"575","article-title":"Urticaria and angioedema","author":"Saini","year":"2014"},{"key":"10.1016\/j.jaci.2026.01.027_bib28","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: a review","volume":"332","author":"Kolkhir","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2026.01.027_bib29","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jaip.2021.03.049","article-title":"The diagnostic workup in chronic spontaneous urticaria\u2014what to test and why","volume":"9","author":"Metz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib30","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.anai.2024.10.026","article-title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine","volume":"134","author":"Lang","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","article-title":"Update on the treatment of chronic spontaneous urticaria","volume":"85","author":"Kolkhir","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2026.01.027_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","article-title":"Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis","volume":"81","author":"Wertenteil","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaip.2022.11.006","article-title":"Urticaria and angioedema: understanding complex pathomechanisms to facilitate patient communication, disease management, and future treatment","volume":"11","author":"Konstantinou","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib37","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaci.2022.10.004","article-title":"Chronic spontaneous urticaria guidelines: what is new?","volume":"150","author":"Zuberbier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101068","article-title":"Diagnostic testing for chronic spontaneous urticaria with or without angioedema: the do\u2019s, don\u2019ts and maybe\u2019s","volume":"18","author":"Bernstein","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2026.01.027_bib39","article-title":"Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria","volume":"4","author":"Cain","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2026.01.027_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/ACI.0000000000000992","article-title":"Hereditary angioedema: current therapeutic management and future approaches","volume":"24","author":"Lamacchia","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.anai.2024.12.012","article-title":"On-demand treatment of hereditary angioedema attacks: patient-reported utilization, barriers, and outcomes","volume":"134","author":"Christiansen","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2024.12.1079","article-title":"Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines","volume":"155","author":"Cohn","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2314192","article-title":"Oral sebetralstat for on-demand treatment of hereditary angioedema attacks","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jaci.2024.11.035","article-title":"Clinical response and corresponding blood transcriptome pathways before and after treatment of hereditary angioedema prodromes compared to active swelling attacks","volume":"155","author":"Ghosh","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1710-1492-6-15","article-title":"Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor","volume":"6","author":"Bork","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib46","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jaip.2023.01.023","article-title":"Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns","volume":"11","author":"Riedl","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clim.2011.07.002","article-title":"A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor","volume":"141","author":"Bork","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13223-024-00910-x","article-title":"Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada","volume":"20","author":"Adatia","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12016-021-08842-9","article-title":"Roles of immune cells in hereditary angioedema","volume":"60","author":"Ferrara","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.iac.2024.03.011","article-title":"Contact system activation and bradykinin generation in angioedema: laboratory assessment and biomarker utilization","volume":"44","author":"Christiansen","year":"2024","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2026.01.027_bib51","article-title":"Bradykinin measurement by liquid chromatography tandem mass spectrometry in subjects with hereditary angioedema enhanced by cold activation","volume":"4","author":"Chen","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2026.01.027_bib52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib53","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.anai.2017.01.029","article-title":"Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks","volume":"118","author":"Bernstein","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib54","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","article-title":"Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks","volume":"124","author":"Craig","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106216","article-title":"Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency","volume":"80","author":"Andr\u00e1si","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2026.01.027_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ab8fe636-8b5b-420e-9cbf-1bef0a19b63f","article-title":"Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment","volume":"8","author":"Maurer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2026.01.027_bib57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"issue":"5, suppl 1","key":"10.1016\/j.jaci.2026.01.027_bib58","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.anai.2025.08.112","article-title":"Hereditary angioedema prophylaxis with prekallikrein SIRNA\u2014phase 1 safety outcomes and prekallikrein levels","volume":"135","author":"Wong","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10375","key":"10.1016\/j.jaci.2026.01.027_bib59","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(22)02406-0","article-title":"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial","volume":"401","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.01.027_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70118","article-title":"Sebetralstat for on-demand treatment of mucosal hereditary angioedema attacks in KONFIDENT-S","volume":"15","author":"Bernstein","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib61","unstructured":"Magerl M, Anderson J, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Baeza ML, Bouillet L, Chapdelaine H, et al. Treatment of HAE attacks with deucrictibant: RAPIDe-1 phase 2 trial results. GA2LEN UCARE Conference 2023, S\u00e3o Paulo, Brazil, 7-9 December, 2023."},{"key":"10.1016\/j.jaci.2026.01.027_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2024.03.007","article-title":"Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized\u2013controlled trial","volume":"154","author":"Petersen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib63","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib64","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib65","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2026.01.027_bib66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib67","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cts.13192","article-title":"Pharmacokinetic\/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated factor XII inhibitor garadacimab (CSL312)","volume":"15","author":"Pawaskar","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"10382","key":"10.1016\/j.jaci.2026.01.027_bib68","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.01.027_bib70","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2352-3026(24)00081-4","article-title":"Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study","volume":"11","author":"Craig","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2026.01.027_bib71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2500\/aap.2025.46.250027","article-title":"Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema","volume":"46","author":"Guilarte","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2026.01.027_bib72","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","article-title":"Inhibition of prekallikrein for hereditary angioedema","volume":"386","author":"Fijen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"issue":"6 suppl","key":"10.1016\/j.jaci.2026.01.027_bib74","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.anai.2024.08.141","article-title":"Phase 2 open-label extension of donidalorsen in patients with hereditary angioedema: a week 197 analysis","volume":"133","author":"Manning","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6, suppl","key":"10.1016\/j.jaci.2026.01.027_bib75","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.anai.2024.08.140","article-title":"Donidalorsen for hereditary angioedema: results from the OASISplus open-label extension study","volume":"133","author":"Tachdjian","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.anai.2025.03.016","article-title":"Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults","volume":"135","author":"Lumry","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib78","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaip.2023.12.025","article-title":"Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema","volume":"12","author":"Riedl","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib79","first-page":"AB194","article-title":"Long-term safety and efficacy of oral deucrictibant for prophylaxis in hereditary angioedema: results of the CHAPTER-1 open-label extension study","volume":"155","author":"Riedl","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5, suppl 1","key":"10.1016\/j.jaci.2026.01.027_bib80","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.anai.2025.08.034","article-title":"Long-term safety and efficacy of oral deucrictibant for prophylaxis in hereditary angioedema: CHAPTER-1 open-label extension","volume":"135","author":"Riedl","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1056\/NEJMoa2405734","article-title":"CRISPR-based therapy for hereditary angioedema","volume":"392","author":"Cohn","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib82","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib83","series-title":"Intellia therapeutics announces positive three-year data from phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress","year":"2025"},{"key":"10.1016\/j.jaci.2026.01.027_bib84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.iac.2024.03.004","article-title":"Chronic spontaneous urticaria: quality of life and economic impacts","volume":"44","author":"Keller","year":"2024","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2026.01.027_bib85","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib86","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.jaip.2023.08.020","article-title":"Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment\u2014results from CURE","volume":"11","author":"Buttgereit","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib87","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/all.15603","article-title":"Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances","volume":"78","author":"Kaplan","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib88","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/all.13430","article-title":"Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU","volume":"73","author":"Sussman","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.251","article-title":"Burden of angioedema among patients with chronic spontaneous urticaria in the United States","volume":"153","author":"Balp","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaci.2025.04.004","article-title":"Endotypes of chronic spontaneous urticaria and angioedema","volume":"156","author":"Wong","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib91","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib92","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib93","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cei.13428","article-title":"Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria","volume":"200","author":"Asero","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70069","article-title":"Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study","volume":"15","author":"Grattan","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib95","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/all.16446","article-title":"CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3 study","volume":"80","author":"Saini","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib96","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMra2120166","article-title":"Chronic urticaria","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib98","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jaip.2014.06.004","article-title":"Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria","volume":"2","author":"Morgan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib100","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/ced\/llaf110","article-title":"Patient-reported outcome measures for chronic spontaneous urticaria: a strategy centred on optimizing patient management","volume":"50","author":"Nettis","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib101","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaip.2017.10.001","article-title":"The urticaria activity score\u2014validity, reliability, and responsiveness","volume":"6","author":"Hawro","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib102","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib104","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib105","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1398-9995.2005.00833.x","article-title":"A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL)","volume":"60","author":"Baiardini","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib106","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2580374","article-title":"Comparative efficacy of omalizumab, dupilumab, and remibrutinib in chronic spontaneous urticaria: a network meta-analysis of randomized control trials","volume":"36","author":"Xiong","year":"2025","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaci.2026.01.027_bib107","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/all.15813","article-title":"Urticaria Control Test real-world performance: a post-hoc analysis","volume":"79","author":"Salameh","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/all.13271","article-title":"Comparison and interpretability of the available urticaria activity scores","volume":"73","author":"Hawro","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12328","article-title":"CRUSE\u00ae\u2014An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria","volume":"14","author":"Neisinger","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5339\/qmj.2023.sqac.14","article-title":"CRUSE\u2014WHAT the first 100 days have taught us","volume":"2023","author":"Neisinger","year":"2023","journal-title":"Qatar Med J"},{"key":"10.1016\/j.jaci.2026.01.027_bib111","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/all.16371","article-title":"Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: a CRUSE\u00ae mobile health study","volume":"80","author":"Sousa-Pinto","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib112","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaci.2024.05.026","article-title":"Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials","volume":"154","author":"Rayner","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib113","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjd.16379","article-title":"Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria","volume":"179","author":"Curto-Barredo","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000491530","article-title":"Omalizumab updosing for better disease control in chronic spontaneous urticaria patients","volume":"177","author":"Kocat\u00fcrk","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib116","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Vena","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib117","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.jaip.2024.05.046","article-title":"Decisions with patients, not for patients: shared decision-making in allergy and immunology","volume":"12","author":"Mack","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib118","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib119","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jaip.2023.06.027","article-title":"Potential therapeutic approaches for chronic urticaria: beyond H1-antihistamines and biologics","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.027_bib120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.iac.2024.07.001","article-title":"Chronic spontaneous urticaria: current and emerging biologic agents","volume":"44","author":"Bernstein","year":"2024","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2026.01.027_bib121","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2026.01.027_bib122","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling\u2014a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib123","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib124","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaci.2026.01.027_bib125","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2026.01.027_bib126","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib127","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.027_bib128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","article-title":"Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial","volume":"161","author":"Gim\u00e9nez-Arnau","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11882-023-01123-9","article-title":"Mast cell\u2013targeting therapies in mast cell activation syndromes","volume":"24","author":"Sabato","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2026.01.027_bib130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/13543784.2023.2277385","article-title":"Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development","volume":"32","author":"Wedi","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaci.2026.01.027_bib131","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.027_bib132","series-title":"Celldex presents unprecedented 76 week results from barzolvolimab phase 2 study in chronic spontaneous urticaria at EAACI Congress, 2025","year":"2025"},{"key":"10.1016\/j.jaci.2026.01.027_bib133","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"issue":"2, suppl","key":"10.1016\/j.jaci.2026.01.027_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.215","article-title":"BLU-808, a potent and selective small molecule inhibitor of wild-type c-KIT for mast cell disorders","volume":"153","author":"Grassian","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","article-title":"Chronic urticaria and the pathogenic role of mast cells","volume":"72","author":"Elieh-Ali-Komi","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2026.01.027_bib136","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib137","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fncel.2019.00299","article-title":"Heterogeneity of human mast cells with respect to MRGPRX2 receptor expression and function","volume":"13","author":"Varricchi","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.jaci.2026.01.027_bib138","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2025.03.007","article-title":"MRGPRX2 gain-of-function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria","volume":"156","author":"Ye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1466058","article-title":"Case report: exploration of abrocitinib in the treatment of refractory chronic spontaneous urticaria: a case series","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2013.11.029","article-title":"Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice","volume":"18","author":"Yamaki","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2026.01.027_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1443704","article-title":"The JAK1\/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells","volume":"15","author":"Poto","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib142","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","article-title":"Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera","volume":"8","author":"S\u00f8rensen","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2026.01.027_bib143","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2340\/00015555-3006","article-title":"Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria","volume":"98","author":"Fukunaga","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2026.01.027_bib144","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaci.2026.01.027_bib145","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaci.2026.01.027_bib146","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15932","article-title":"Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis","volume":"35","author":"Mansouri","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2026.01.027_bib147","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/ijd.ijd_1085_23","article-title":"An open-label, investigator-initiated, single-centre pilot study to determine the safety and efficacy of tofacitinib in resistant chronic spontaneous urticaria","volume":"69","author":"De","year":"2024","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2026.01.027_bib148","doi-asserted-by":"crossref","first-page":"AB372","DOI":"10.1016\/j.jaci.2023.11.891","article-title":"Efficacy and safety of TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamine: results from a phase \u2160b study","volume":"153","author":"Lu","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.027_bib149","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/medicina58060816","article-title":"Current and future approaches in management of chronic spontaneous urticaria using anti-IgE antibodies","volume":"58","author":"Orzan","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jaci.2026.01.027_bib150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5414\/ALX02204E","article-title":"Use of biologics in chronic spontaneous urticaria\u2014beyond omalizumab therapy?","volume":"5","author":"Metz","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.jaci.2026.01.027_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111706","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of YH35324, a novel long-acting high-affinity IgETrap-Fc protein in subjects with atopy: results from the first-in-human study","volume":"130","author":"Ye","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2026.01.027_bib152","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4168\/aair.2025.17.2.181","article-title":"Therapeutic efficacy of YH35324 on Fc\u03b5RI\u03b1-mediated mast cell\/basophil activation","volume":"17","author":"Ryu","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2026.01.027_bib153","doi-asserted-by":"crossref","first-page":"AB212","DOI":"10.1016\/j.jaci.2024.12.656","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of YH35324, a novel long-acting high-affinity IgETrap-Fc fusion protein, in patients with chronic spontaneous urticaria refractory to H1 antihistamines","volume":"155","author":"Ye","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:54:33Z","timestamp":1775210073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0091674926000813"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.01.027","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in hereditary angioedema and chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}